The Healey Center for ALS is a global leader in innovative clinical trials. Our first ever HEALEY ALS Platform Trial is now underway, testing four promising investigational products simultaneously. This platform was developed in conjunction with researchers, people living with ALS and families, clinicians and regulatory agencies and, as a result, has the fastest patient enrollment rate of any ALS trial.
Unlike the traditional approach to testing investigational products, which requires building the infrastructure, then tearing it down and starting from scratch for the next trial, once the structure of the platform is in place, new investigational products can be added without stopping and restarting the trial, while investigational products that are not effective can be dropped. As a result, we can dramatically accelerate our search for effective treatments, cut costs, increase the number of participants receiving an active therapy rather than a placebo, and reduce the total length of time needed to evaluate an investigational product. Best of all, we can keep testing therapies, without stopping, until we find the cures.
"I lost the privilege of working on the human time clock on January 6, 2018. The ALS clock is a lot faster," - Sandy, a person with ALS.
Thanks to the support of philanthropy, 52 sites are currently up and running with HEALEY ALS Platform Trial (with more being added soon!), over 300 trial participants have been enrolled, and we plan on adding 2-3 new investigational products for testing every year.
Learn more about this groundbreaking trial, designed to accelerate the development of effective treatments for people living with ALS, in the video below.